Renal Denervation for Uncontrolled Hypertension
January 14, 2025
Renal Denervation for Uncontrolled Hypertension
Renal denervation (RDN) has gained momentum as a promising treatment for uncontrolled hypertension. It involves using catheters to ablate renal sympathetic nerves, aiming to reduce blood pressure in patients who do not respond adequately to medications and lifestyle changes. This minimally invasive procedure received significant attention following the U.S. FDA approval of two systems: Recor Medical’s Paradise Ultrasound RDN system and Medtronic’s Symplicity Spyral RDN system.
The Centers for Medicare & Medicaid Services (CMS) showed support for RDN by introducing new transitional pass-through (TPT) payments in the 2025 Medicare Hospital Outpatient Prospective Payment System, aimed at supporting new technologies with consistent reimbursement for up to three years.
https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=318
